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Abstract
 Background—Noninvasive estimation of the degree of inflammation seen on kidney biopsy 
with lupus nephritis (LN) remains difficult. The objective of this study was to develop a Renal 
Activity Index for Lupus (RAIL) that, based solely on laboratory measures, accurately reflects 
histological LN activity.
 Methods—We assayed traditional LN laboratory tests and 16 urine biomarkers (UBMs) in 
children (n=47) at the time of kidney biopsy. Histological LN activity was measured by the NIH 
Activity Index (NIH-AI) and the Tubulointerstitial Activity Index (TIAI). High LN-activity status 
(vs. moderate/low) was defined as NIH-AI scores > 10 (vs. ≤ 10) or TIAI scores >5 (vs. ≤ 5). 
RAIL algorithms that predicted LN-activityNIH-AI and LN-activityTIAI status were derived by 
stepwise multivariate logistical regression, considering traditional biomarkers and UBMs as 
candidate components. The accuracy of the RAIL for discriminating by LN-activity status was 
determined.
 Results—The differential excretion of six UBMs (NGAL, MCP-1, ceruloplasmin, adiponectin, 
hemopexin, KIM-1) standardized by urine creatinine was considered in the RAIL. These UBMs 
predicted LN-activityNIH-AI status with >92% accuracy and LN-activityTIAI status with >80% 
accuracy. RAIL accuracy was minimally influenced by concomitant LN damage. Accuracies 
between 71 and 85% were achieved without standardization of the UBMs. The strength of these 
UBMs to reflect LN-activity status was confirmed by principal component and linear discriminant 
analyses.
Brunner et al. Page 2
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 Conclusion—The RAIL is a robust and highly accurate noninvasive measure of LN-activity. 
The measurement properties of the RAIL, which reflect the degree of inflammatory changes as 
seen on kidney biopsy, will require independent validation.
Key Indexing Terms
SLE; lupus nephritis; kidney biopsy; biomarker
 INTRODUCTION
Systemic Lupus Erythematosus (SLE) is a multi-system inflammatory autoimmune disease, 
and renal involvement is one of the main determinants of poor prognosis (1). The 
pathogenesis of lupus nephritis (LN) involves kidney deposition of immune complexes in 
the setting of impaired apoptosis regulation (2). There are three principal patterns of injury 
with LN. Firstly, a mesangial pattern which features mesangial hypercellularity and matrix 
deposits as a response to mesangial immune complex accumulation. Secondly, a 
proliferative pattern that occurs in response to subendothelial immune complex buildup and 
is characterized by obliteration of glomerular capillary lumens due to leukocyte 
accumulation, mesangial proliferation, often capillary wall destruction, and rupture of 
Bowman’s capsule resulting in extra-capillary crescent formation. Lastly, in the 
membranous pattern there is increased immune complex deposition in the sub-epithelial 
space with leads to cytotoxic injury to the podocyte, and result in the thickening of the 
glomerular basement membrane. These three patterns are the basis for the categorization of 
LN in the International Society of Nephrology/Renal Pathology Society (ISN/PRS) 
Classification (3).
Recently, novel urine biomarkers (UBM) have been described that can assist with 
diagnosing active LN and anticipate LN flares (4–8). Among others, we have provided 
initial evidence that the urine concentrations of some of the UBMs are associated with 
distinct histological changes of LN (9). Since our initial studies, additional UBMs have been 
proposed by other investigators. The 16 most promising of these UBMs were considered in 
this study: neutrophil gelatinase associated lipocalin (NGAL), monocyte chemotactic protein 
1 (MCP-1), ceruloplasmin, adiponectin, hemopexin, kidney injury molecule 1 (KIM-1), 
alpha-1-acid glycoprotein (AAG), transforming growth factor beta (TGF-β), hepcidin, 
lipocalin-like prostaglandin synthase (L-PGDS), transferrin, vitamin D binding protein 
(VDBP), microalbumin, cystatin- C, endothelial protein C receptor (EPCR), and liver type 
fatty acid-binding protein 1 (L-FABP).
We hypothesized that a selection of these UBMs, alone or in combination with traditional 
measures of LN, can accurately quantify the degree of histological LN activity. Hence, the 
objective of this study was to develop in children and young adults a Renal Activity Index 
for Lupus (RAIL) to non-invasively measure LN activity.
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 MATERIALS & METHODS
 Patients
Patients diagnosed with childhood-onset SLE (10) who required a kidney biopsy as part of 
standard of care participated in this cross-sectional study. At the time of kidney biopsy, a 
random urine sample was collected for UBM testing. Prospectively, relevant clinical 
information and traditional measures of LN were recorded, including the glomerular 
filtration rate (GFR) (11, 12) and the protein to creatinine ratio (P/C ratio) in a random urine 
sample. All patients received therapy for childhood-onset SLE at the time of the urine 
collection and biopsy. There were five patients with repeat biopsies.
The renal domain score of the Systemic Lupus Disease Activity Index (SLEDAI-R; range 0 
– 16; 0 = inactive LN) (13) and that of the Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology Damage Index (SDI-R; range 0– 3; 0= no LN 
damage) (14) were also completed and served as measures of LN clinical activity and 
damage, respectively.
 Kidney Histology
The histological characteristics of each kidney biopsy were interpreted in a blinded fashion 
by one expert nephropathologist (DW) as per the ISN/RPS Classification (3, 15). Most 
studies in LN employ a previously developed scoring system to quantify the amount of 
overall LN activity, using the National Institutes of Health Activity Index (NIH-AI; score 
range 0–24; 0= inactive) (16). Because the NIH-AI is focused on acute glomerular injury 
with LN, we also measured the Tubulointerstitial Activity Index (TIAI; score range: 0–21; 
0=no interstitial activity) (17). The NIH Chronicity Index was scored (NIH-CI; score range 0 
– 12; 0 = no LN-chronicity) to quantify LN damage as seen on kidney biopsy (16). The 
ISN/RPS Classification, the NIH-AI, TIAI and the NIH-CI have all been validated for use in 
children and adults (18, 19).
 Urinary Biomarker Assays
The following 16 UBMs were measured: NGAL, MCP-1, ceruloplasmin, adiponectin, 
hemopexin, KIM-1, AAG, TGF-β, hepcidin, L-PGDS, transferrin, VDBP, microalbumin, 
EPRC, cystatin-C and L-FABP. Laboratory personnel assaying the UBMs were blinded to 
clinical and histological information. Spun urine samples were stored at 0°C within 1 hour 
of collection and frozen at −80°C prior within 24 hours prior to batch processing.
Unless stated otherwise, UBMs were quantified using commercial ELISA kits as per the 
manufacturers’ instructions, and a four parameter logistic curve-fit was used to fit the 
standard curve. In the following, inter-assay and intra-assay variability of these assays is 
expressed in percent of the coefficient of variation [CV inter/intra].
NGAL [CV inter/intra: 1.0%/9.1%] was measured by ELISA (Human NGAL ELlSA; 
Bioporto, Grusbakken, Denmark). Ceruloplasmin [CV inter/intra: 4.1% /7.1%] was 
quantified by ELISA (Assaypro, St.Charles, MO); AAG [CV inter/intra: 5.0%/ 8.5%] by 
ELISA (R&D Systems, Minneapolis, MN); MCP-1 [CV inter/intra: 5.0%/5.9%] by ELISA 
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(R&D Systems, Minneapolis, MN); VDBP [CV inter/intra: 5.1%/6.2%] by ELISA (R&D 
Systems, Minneapolis, MN); and hepcidin-25 [CV inter/intra: 3.5%/3.4%] was measured by 
ELISA (EIA kit S-1337, Peninsula Laboratories, San Carlos, CA). Adiponectin [CV inter/
intra: 4.0%/9.9%] was measured using the Quantikine ELISA Human HMW Adiponectin/
Acrp30 (R&D Systems, Minneapolis, MN); hemopexin [CV inter/intra: 4.8%/7.3%] with 
the AssayMax Human Hemopexin ELISA Kit (Assaypro, St. Charles, MO); EPCR [CV 
inter/intra: 7.8%/9.0%] with the DuoSet Human EPCR kit (R&D Systems, Minneapolis, 
MN); and L-FABP [CV inter/intra: 6.1%/10.9%] by ELISA (CMIC Co., Tokyo, Japan), 
respectively. The KIM-1 assay was constructed using commercially available reagents 
(Duoset DY1750, R & D Systems, Minneapolis, MN) as described previously (20). Urine 
creatinine measurements were made using a modified Jaffe reaction, and microalbumin 
(MALB) was measured by immunoturbidimetry, both on a Dimension Xp and plus HM 
Clinical Analyzer (Siemens, Munich, Germany). Coefficients of variability for the creatinine 
measurements were 2.4% (intra) and 4.2% (total), and 2.9% (intra) and 5.9% (inter) for 
MALB.TGF-β [CV inter/intra: 2.6%/8.3%] was measured by ELISA (R&D Systems, 
Minneapolis, MN) after acid activation. Briefly, 20 μL of 1N HCl was added to 100 μL of 
urine sample, mixed by inversion and incubated at room temperature for 10 minutes. Next, 
the acidified sample was neutralized by adding 20 μL of 1.2 N NaOH/0.5 M HEPES, then 
the assay was immediately run per manufacturer’s instructions [CV inter/intra: 2.0%/7.8%].
Using immunonephelometry (Siemens, BNII, Munich, Germany) we measured cystatin-C 
[CV inter/intra: 2.5%/2.3%], transferrin [CV inter/intra: 3.4%/2.5%] and L-PGDS [CV inter/
intra: 2.3%/6.5%].
Concentrations of the UBMs (in ng/ml: for NGAL, CP, L-FABP, VDBP, adiponectin, EPCR, 
hemopexin, hepcidin; in pg/ml: for KIM-1 and TGF-β; in pg/ml: MCP-1: in mg/dl: for 
transferrin and L-PDGS; in mg/L for cystatin-C and microalbumin) were standardized for 
urine creatinine levels (in mg/mL).
 Statistical analysis
The candidate predictors considered for inclusion in the RAIL were the 16 UBMs and the 
traditional measures of LN. LN-activity status served as the dependent variable in the 
statistical procedures to derive the RAIL and was defined as high versus (vs.) moderate/low 
based on the scores of the NIH-AI and TIAI, respectively. LN-ActivityNIH-AI was classified 
as high when NIH-AI scores were >10, and moderate to low when NIH-AI scores were ≤10; 
LN-ActivityTIAI was considered high for TIAI scores >5, and moderate to low for LN-
ActivityTIAI scores ≤5. The pool of the candidate RAIL-predictors (standardized UBMs, 
traditional biomarkers) to be considered in the multivariate models was informed by 
univariate models under a threshold p-value of ≤0.2 for discrimination of high from 
moderate/low LN-activity (LN-activityNIH-AI; LN-activityTIAI). In primary analysis, 
stepwise selection was used in multiple logistical regression models to identify the 
components of the RAIL. In secondary analysis, we considered raw amounts of the UBMs 
rather than standardized UBMs. The appropriateness of the final RAIL predictors to reflect 
LN-activity status was confirmed by linear discriminant analysis (21) and principal 
component analysis, adjusted and unadjusted for LN chronicity (NIH-CI score).
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The accuracies of RAIL algorithms was considered outstanding, excellent, good, and fair if 
the area under the receiver operating characteristic curve (AUC) was in the range of 0.9–1.0, 
0.81–0.90, 0.71–0.80, and 0.61–0.70, respectively. We also determined sensitivity, 
specificity, the positive (LR+) and the negative likelihood ratios (LR−) for the statistical 
optimal receiver operating characteristic (ROC) curve cutoff. Here, LR+ values can be 
interpreted as: > 10: large, often conclusive increase in the likelihood of “ruling in” the 
presence of high LN-activity status; 5 – 9.9: moderate increase; and 2 – 4.9: small increase, 
respectively. In other words, a LR+ of 2 increases the probability for a high LN-activity 
status by 15%, a LR+ of 5 increases it 30%, and one of 10 increases it even by 45% (22). LR
− are interpreted accordingly for “ruling-out” active LN. Statistical analyses were done 
using SAS version 9.4 software (SAS, Cary, NC, USA). P-values < 0.05 were considered 
statistically significant. The study was approved by the Institutional Review Boards and 
Ethics Review Committees of the participating centers. Additional details on the statistical 
analyses are provided online.
 RESULTS
 Patient characteristics & features of kidney biopsy
A total of 47 patients with LN were included in this study (Table 1). At the time of the study, 
on average, their [SD; standard deviation] age was 15.7 [3.01] years, their extrarenal 
SLEDAI score was 9.7 [8.20], and the time interval between kidney biopsy and urine 
collection was 0 [3] days. None of the patients had Class 1 or 6 LN. As expected, 
histological features of LN activity and chronicity were seen often concomitantly in the 
same biopsy. SDI-R scores were positive in 15 (32%) patients. Given the quality of the 
biopsy specimens, NIH-AI, TIAI and NIH-CI scores were not assigned to all biopsies, hence 
were only available for 41, 32 and 40 of the biopsies, respectively. The high and 
moderate/low NIH-AI consisted of 20 and 21 patients; there were 10 and 22 patients in the 
high and moderate/low TIAI as well as 21 patients with NIH-CI scores over 0.
 Associations of noninvasive measures kidney histology indices
As is summarized in Table 2, proteinuria did not significantly differentiate patients by LN-
activity status (NIH-AI, TIAI) or LN-chronicity status (NIH-CI score > 0 vs. 0), irrespective 
of adjustment for angiotensinogen system blocking medications. The GFR was lower with 
high LN-activity status and with NIH-CI scores > 0. Seven UBMs significantly differed with 
LN-activityNIH-AI status and six UBMs with LN-activityTIAI status (Table 3). Notably, 
MCP-1, adiponectin, and TGF-β significantly differed with both LN-activityNIH-AI and LN-
activityTIAI status.
 Associations of noninvasive measures kidney histology features
We then assessed the differential excretion of the UBMs with the presence vs. absence of 
individual histological findings reflective of active inflammation in LN (Figure 1). NGAL, 
MCP-1, KIM-1 and L-PGDS were all markedly elevated in the urine of patients whose 
kidney biopsy showed endocapillary hypercellularity compared to those that did not. 
Likewise, NGAL, KIM-1 and MCP-1 were found in higher concentrations in patients whose 
kidney biopsy showed tubular cell flattening and necrosis. There were significantly higher 
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urine levels of NGAL, but not MCP-1 or KIM-1, in patients with vs. without tubular cell 
pyknosis and epithelial cells in the tubular lumen. EPCR was not associated with any 
specific histological feature considered in the TIAI or NIH-AI; while TGF-β, AAG, cystatin-
C and L-FABP were only differentially expressed with select histological features scored in 
the TIAI but with none of the features reflected by the NIH-AI.
Most of the UBMs were weakly (Pearson correlation coefficient r; |0.2| ≤ r < |0.4|) correlated 
with the P/C ratio but none was strongly correlated (r > |0.6|). The GFR was only moderately 
correlated with NGAL, weakly correlated only with MCP-1, VDBP, hemopexin and KIM-1, 
and unrelated to the levels of all other UBMs. Levels of complement C3 and C4 were no 
more than weakly correlated with any of the UBMs. As expected, the levels of UBMs were 
differentially associated with each other (see supplemental Figure 2).
 UBMs and ISNPRS Class
The mean (95%CI) L-FABP levels were significantly lower with LN Class 3, 4 or 5 vs. LN 
Class 2 [0.24 (0.16, 0.36) vs. 0.97 (0.26, 3.62); p=0.05]. Similarly, cystatin-C levels 
significantly differed between LN Class 3, 4 or 5 vs. LN Class 2 [0.72 (0.52, 0.99) vs. 3.27 
(1.16, 9.20); p=0.010]. Taken together, urine L-FABP levels of >1.0 decreased the likelihood 
of presence of Class 3,4 or 5 LN by 30% (LR− 0.2) while cystatin-C levels of >3.3 
decreased the likelihood of LN Class 3, 4 or 5 by about 23% (LR− 0.29).
 Individual noninvasive LN measures and LN-activity status
Table 3 compares means of LN measures between patients with and without LN activity, 
after correcting for concomitant LN damage ((NIH-CI score). In addition, each LN marker 
was used to predict LN activity using a ROC-analysis. The results revealed that KIM-1 was 
the single best UBM for capturing LN-activityNIH-AI status [AUC (95% CI): 0.86 (0.74, 
0.98)] followed by MCP-1, NGAL and adiponectin which were at least good predictors [all 
AUCs (95% CI) ≥ 0.70 (0.54, 0.98)]. Irrespective of adjustment for concurrent kidney 
damage, MCP-1, VDBP, cystatin-C, TGF-β, L-PGDS and hemopexin were all at least good 
predictors of LN-activityTIAI status. Similarly, GFR was a good predictor of LN-activity 
status (Table 2).
 Development of a combinatorial biomarker of LN-activity status
In stepwise multiple logistical modeling, we identified NGAL, ceruloplasmin, MCP-1, 
adiponectin, hemopexin and KIM-1 as the best predictors (RAIL-UBMs) of LN-activityTIAI 
status and LN-activityNIH-AI status (Figure 2; supplemental Tables 2). Traditional LN 
measures did not remain in the pool of covariates best suited to predict LN-activity status. 
The accuracy of the Rail-UBMs in reflecting the LN-activity status was well preserved in 
models correcting for concurrent LN damage (NIH-CI score) or even when considering 
simply the raw amounts of the RAIL-UBMs (Supplemental Figure 3).
Besides multiple logistical regression models, other methods such as linear discriminant or 
principal component analyses have been shown to yield composite scores for measuring 
complex constructs. The suitability of the RAIL-UBMs for predicting histological correlates 
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of active LN is supported by congruent results, using linear discriminate and principal 
component analyses (Table 4).
 Proposed RAIL algorithm
Given that the NIH-AI is more commonly used in clinical practice than the TIAI and 
because one must assume that information on LN chronicity will not readily be available in a 
clinical setting, we propose the following algorithm that considers log-transformed urine 
concentrations (creatinine standardized) of the six RAIL-UBMs: RAIL score = − 4.29 –
0.34* NGAL −0.06*ceruloplasmin + 0.89* MCP-1+ 0.18* adiponectin − 0.65 * hemopexin 
+ 0.62 * KIM-1. A RAIL-score of ≥ 0.39 will correctly identify 90% of all cases with high 
LN-activity status with a false positive rate being controlled at 14% (Figure 2, Panel A).
 DISCUSSION
At present, accurate of LN activity requires a kidney biopsy. Based on detailed assessment 
of the measurement properties of traditional and 16 novel urinary biomarkers of LN, we 
newly propose a Renal Activity Index for Lupus (RAIL) to noninvasively quantify LN 
activity. The accuracy of the RAIL is minimally influenced by concurrent LN chronicity and 
reflects both glomerular and tubulointerstitial inflammation with LN. Further, concurrent use 
of medications, including those targeting the renin-angiotensin-aldosterone system, do not 
seem to influence the accuracy of the RAIL to a large degree.
The UBMs included in the RAIL are all involved in putative mechanisms aimed at 
protecting kidneys from damage due to renal inflammation. Indeed, there is a strong 
biological rationale for each of the six RAIL UBMs. NGAL is rapidly induced by active 
inflammation with LN, and promptly declines with therapy (4). In the acute setting, NGAL 
appears to be a part of a protective anti-apoptotic mechanism that limits tubule cell damage 
and enhances proliferation (23). MCP-1 is induced by type I interferons and is known to be a 
predictive biomarker of LN flares and LN severity (5, 24). There is high expression of 
MCP-1, especially in the tubular epithelial cells (25) with oxidative stress. The antioxidant 
ceruloplasmin is a copper-containing ferroxidase that can transform ferrous iron, which is 
highly damaging to kidney tubules, to its nontoxic ferric configuration. High ceruloplasmin 
levels are associated with renal tissue remodeling as can be observed with LN (4, 26).
The cytokine adiponectin is present on the endothelium of intrarenal vasculature and to a 
lesser extent in the proximal and distal tubular epithelial cells (27), has anti-inflammatory 
properties, and urinary concentrations increase with kidney injury, including with LN. 
Among the UBMs considered, we found only adiponectin to be closely correlated with 
albuminuria. High levels of adiponectin levels were present in the setting of high glomerular 
and interstitial inflammation with LN.
Hemopexin, a protease that protects kidney tubules from toxicity of free heme radicals, is 
produced primarily in the renal cortex in the setting of nephrotoxic insults (28). We found 
hemopexin levels closely related to glomerular leukocyte infiltrates, subendothelial deposits 
and interstitial inflammation with LN. The protective role of hemopexin in LN is supported 
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by the observation that urine levels of hemopexin were highest with Class 2 LN (data not 
shown).
KIM-1 is responsible for the clearance of debris from damaged renal tubules and assists with 
the regeneration of the epithelium. Urine KIM-1 levels increase in the setting of proximal 
tubule injury and interstitial inflammation as can occur with LN (29).
One of our earlier studies suggested that the combination of MCP-1, ceruloplasmin, AAG 
and the P/C ratio has excellent accuracy in estimating histological LN activity (9). While we 
confirm the usefulness of ceruloplasmin and MCP-1 in quantifying LN-activity, we believe 
that the current study has several new strengths. First, different from our earlier study, the 
majority of the urine samples were collected on the day of kidney biopsy and the 
interpretation of the kidney biopsies occurred by a single expert nephropathologist. Second, 
we increased the pool of candidate UBMs and assessed both tubulointerstitial and 
glomerular features of active inflammation with LN; and third, we considered concomitant 
LN damage. Nonetheless, previous results are in line with our current findings, given the 
association of the levels of the various UBMs with each other and also with distinct 
histological features of LN-activity (4, 7, 9).
The UBMs considered in the RAIL were not well suited to discriminate between the 
different Classes of LN. Conversely, higher urine levels of two non-RAIL markers (L-FABP 
levels and cystatin-C) were associated with less severe LN (Class 2 as compared to Class 3, 
4 or 5).
Our study must be seen in the light of certain limitations. Given the diverse medication 
regimens used, the multiplicity of distinct kidney biopsy features and their considerable 
overlap in a given patient, our study findings will need to be confirmed in a larger cohort. 
However, rigorous statistical methodology was employed and provided consistent results, 
irrespective of consideration of potential effect modifiers, supporting the robustness of our 
findings.
If confirmed in ongoing experiments, the RAIL will allow for more effective and 
personalized monitoring of LN and its therapy. The availability of standardized clinical 
platforms for the combined measurement of the urinary biomarkers will enable the testing of 
this hypothesis in the near future (30). Future research will need to confirm the most 
appropriate cut-off scores for the RAIL and also investigate how the combinatorial RAIL-
UBMs can be used to non-invasively predict response to therapy.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE & INNOVATIONS
• We propose a renal activity index for lupus (RAIL) based on the urine 
concentrations of six protein biomarkers
• The RAIL quantifies the amount of histological inflammation seen on 
kidney biopsy tissues as measured by the NIH Activity Index with over 
92% accuracy
• Once validated, it is anticipated that the RAIL is used to monitor the degree 
of inflammation with lupus nephritis non-invasively.
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Figure 1. Differences in UBM levels in relationship to histological features of LN group as per the 
components of the LN-Activity Indices from kidney biopsy
& NIH-AI= NIH Activity Index ; TIAI Tubulointerstitial Activity Index
(% of biopsies with features present)
Neutrophil gelatinase associated lipocalin (NGAL), monocyte chemotactic protein 1 
(MCP-1), -PGDS L-prostaglandin synthase, kidney injury molecule 1 (KIM-1), fatty acid-
binding protein 1 (L-FABP), vitamin D binding protein ; EPCR is not shown as it was not 
differentially associated with any of the histological features
P-value from univariate logistic regression to predict presence vs. absence of histological 
features are color coded as follows:
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Figure 2. ROC curves for the Candidate RAIL algorithms
Panels A–D feature receiver operating characteristic curves (ROC) of six UBMs (NGAL, 
ceruloplasmin, MCP-1, adiponectin, hemopexin and KIM-1) considered in the RAIL 
algorithm for identifying predict low/moderate vs. high LN histological activity. Panels A–B 
do not consider concurrently observed LN chronicity while Panels C–D show the accuracy 
of the UBMs after correcting for LN chronicity.
For each of the ROC curves the area under the curve (AUC) is shown. The arrows point 
towards the statistically optimal cut-off score of the ROC-curve and provides for this point 
sensitivity, specificity, positive and negative likelihood ratios (LR+, LR−) information. 
Irrespective of the consideration of LN chronicity (NIH-CI score), the RAIL algorithms. 
Panel A features the preferred RAIL algorithm: RAIL score = −4.29 –0.34* NGAL 
−0.06*ceruloplasmin + 0.89* MCP-1 + 0.18* adiponectin − 0.65 * hemopexin + 0.62 * 
KIM-1.
†LN-activity NIH-AI high vs. moderate/low is defined based on NIH-AI scores > 10 vs. ≤ 10
‡ LN-activity TIAI high vs. moderate/low is defined based on TIAI scores > 5 vs. ≤ 5.
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Table 1
Demographics and clinical information of the patient at the time of urine collection and time of kidney biopsy
Features n of N (%) Mean (SD)
Females 34 (72.3%)
Disease duration (in years) 0.16 [2.62]
Race
Black 19 (40.4%)
White 19 (40.4%)
Asian 1 (2.2%)
Native Indian 0 (0%)
Mixed racial 8 (17%)
Medications
Oral prednisone (mg/day) 37 (78.7%) 42 (19.36)
Pulse methylprednisolone 13 (27.7%)
Mycophenolate mofetil 16 (34.0%)
Azathioprine 1 (2.1%)
Cyclophosphamide 13 (27.7%)
Diuretics 7 (14.9%)
Angiotensin system blocking drug 19 (40%)
LN Status
GFR < 60 ml/min/m2 9 (19.6%)
Protein:creatinine ratio > 0.5 42 (93.3%)
Renal SDI score& 0.26 (0.57)
Renal SLEDAI score 9.66 (5.18)
Complement C3 low 30 (66.7%)
Complement C4 low 34 (75.6%)
Presence of anti-dsDNA antibodies 35 (87.5%)
Histological Features present
ISNRPS ¶
Class 2 3 (6.5%)
Class 3 8 (17.4%)
Class 4 24 (52.2%)
Class 5 11 (23.9%)
NIH-AI ‡ 42 (89.4%) 9.74 (6.50)
TIAI » 34 (72.3%) 4.94 (2.21)
NIH-CI Δ 42 (89.4%) 1.93 (1.97)
&Systemic Lupus International Collaborating Clinics Renal Activity Index, range 0 – 15; 0 = inactive LN
¶
International Society for Nephrology Renal Pathology Society Class; there was no biopsy consistent with Class 1 or 6
‡NIH Activity Index; range 0 – 24; 0 = inactive LN
»
Tubulointerstitial Activity Index; 0 – 21; 0 = no interstitial changes
ΔNIH Chronicity Index; range 0 – 12; 0 = LN without chronic changes
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